9 completed, 4 terminated, 3 suspended, 2 active not recruiting. 23 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 23 | Completed 9, Terminated 4, Suspended 3, Active not recruiting 2, Recruiting 2, Withdrawn 2, Unknown 1 |
| Phase 2 | 7 | Completed 3, Terminated 3, Unknown 1 |
Follow Thyroid Carcinoma, Anaplastic: new trials by email Literature Review of Thyroid Carcinoma, Anaplastic trials Research Report on Thyroid Carcinoma, Anaplastic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial Personalised treatment - Thyroid Cancer Stage IV, Anaplastic Thyroid Cancer | Phase 1 | Recruiting | Radboud University Medical Center | 10 | 2026-10-01 | 2026-10-28 |
| CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors CD70-targeted CAR-T cells - Renal Cell Carcinoma (RCC), Lung Cancer | Phase 1 | Suspended | Chongqing Precision Biotech Co., Ltd | 90 | 2025-09-12 | 2026-09-11 |
| XL092 and Cemiplimab in BRAF WT Thyroid Cancer Cemiplimab, XL092 - Anaplastic Thyroid Cancer, Thyroid Cancer | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 12 | 2025-06-03 | 2026-10-05 |
| A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 JZP815 - Advanced Cancer, Metastatic Cancer | Phase 1 | Active not recruiting | Jazz Pharmaceuticals | 98 | 2022-10-10 | 2026-09-10 |
| The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation HLX208 - Anaplastic Thyroid Cancer, ATC | Phase 1 / Phase 2 | Unknown | Shanghai Henlius Biotech | 25 | 2021-12-10 | 2023-08-21 |
| Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2 - Metastatic Solid Tumor, Colorectal Cancer | Phase 1 / Phase 2 | Terminated | Hutchmed | 87 | 2021-03-05 | 2025-05-08 |
| Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer AIC100 CAR T Cells - Anaplastic Thyroid Cancer, Relapsed/Refractory Poorly Differentiated Thyroid Cancer | Phase 1 | Active not recruiting | AffyImmune Therapeutics, Inc. | 70 | 2020-09-28 | 2025-03-30 |
| Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer Dabrafenib, Intensity-Modulated Radiation Therapy, Trametinib - BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present | Phase 1 | Suspended | City of Hope Medical Center | 6 | 2020-09-14 | 2026-10-15 |
| JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations JSI-1187, Dabrafenib - Solid Tumors | Phase 1 | Suspended | JS InnoPharm, LLC | 71 | 2020-06-18 | 2025-09-03 |
| Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer durvalumab, tremelimumab, Stereotactic Body Radiotherapy (SBRT) - Metastatic Anaplastic Thyroid Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 13 | 2017-04-25 | 2022-06-08 |
| A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer MLN0128 - Anaplastic Thyroid Cancer, Thyroid Cancer | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 46 | 2015-07-01 | 2024-01-12 |
| Phase I/II Study of PDR001 in Patients With Advanced Malignancies PDR001 - Melanoma, Non-small Sell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 319 | 2015-04-27 | 2022-08-03 |
| A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers Adalimumab - Anaplastic Thyroid Cancers | Phase 1 | Withdrawn | Gustave Roussy, Cancer Campus, Grand Paris | 2014-12-01 | 2016-01-26 | |
| Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. PLX8394 - Melanoma, Thyroid Cancer | Phase 1 | Terminated | Fore Biotherapeutics | 5 | 2014-02-01 | 2020-10-19 |
| A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) Crolibulin, Cisplatin - Solid Tumor, Anaplastic Thyroid Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 27 | 2011-01-26 | 2017-04-10 |
| S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors docetaxel, vandetanib, proteomic profiling - Breast Cancer, Head and Neck Cancer | Phase 1 | Withdrawn | SWOG Cancer Research Network | 2008-09-01 | 2017-04-24 | |
| A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel CS-7017, Paclitaxel - Anaplastic Thyroid Cancer | Phase 1 / Phase 2 | Terminated | Daiichi Sankyo | 19 | 2008-01-01 | 2020-09-16 |
| NGR-TNF in Treating Patients With Advanced Solid Tumors CNGRC peptide-TNF alpha conjugate - Colorectal Cancer, Head and Neck Cancer | Phase 1 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 70 | 2004-09-01 | 2012-09-24 |
| Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer filgrastim, pegfilgrastim, cisplatin - Head and Neck Cancer | Phase 1 / Phase 2 | Terminated | Case Comprehensive Cancer Center | 4 | 2003-11-01 | 2010-06-11 |
| Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases boronophenylalanine-fructose complex, sodium borocaptate, conventional surgery - Colorectal Cancer, Head and Neck Cancer | Phase 1 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 27 | 2003-04-01 | 2012-01-20 |
Showing 20 of 23. Sign in to see all of them.
Thyroid Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (7) · Adenocarcinoma, Follicular (6) · Carcinoma, Medullary (6) · Salivary Gland Neoplasms (6) · Colorectal Neoplasms (5) · Head and Neck Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (5) · Thyroid Cancer, Papillary (5) · Carcinoma, Renal Cell (4) · Colonic Neoplasms (4) · Melanoma (4) · Breast Neoplasms (3) · Breast Neoplasms, Male (3)
Carcinoma (23) · Neoplasms by Histologic Type (23) · Neoplasms, Glandular and Epithelial (23) · Neoplasms (20) · Neoplasms by Site (16) · Endocrine Gland Neoplasms (11) · Endocrine System Diseases (11) · Neoplasms, Germ Cell and Embryonal (11) · Neoplasms, Nerve Tissue (11) · Neuroectodermal Tumors (11) · Neuroendocrine Tumors (10) · Thyroid Diseases (10) · Lung Diseases (9) · Respiratory Tract Diseases (9) · Respiratory Tract Neoplasms (9)
Cisplatin (2) · Paclitaxel (2) · Trastuzumab (2) · dabrafenib (2) · 4-boronophenylalanine-fructose (1) · Adalimumab (1) · CCT239065 (1) · Docetaxel (1) · Doxorubicin (1) · Filgrastim (1) · Interleukin-12 (1) · Interleukin-12 Subunit p35 (1) · PLX8394 (1) · Radiosurgery (1) · Radiotherapy (1)
National Cancer Institute (NCI) (3) · Case Comprehensive Cancer Center (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · AffyImmune Therapeutics, Inc. (1) · Chongqing Precision Biotech Co., Ltd (1) · City of Hope Medical Center (1) · Daiichi Sankyo (1) · Dana-Farber Cancer Institute (1) · Fore Biotherapeutics (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Hutchmed (1) · JS InnoPharm, LLC (1) · Jazz Pharmaceuticals (1) · Memorial Sloan Kettering Cancer Center (1) · Novartis Pharmaceuticals (1)
United States (16) · Germany (3) · Netherlands (3) · China (2) · France (2) · Canada (1) · Hungary (1) · Italy (1) · Lebanon (1) · Norway (1) · Poland (1) · Spain (1) · Taiwan (1) · Thailand (1) · Turkey (Türkiye) (1)
Anthony W. Tolcher, MD (1) · Cornelis J. A. Punt, MD, PhD (1) · Donglai Lv, MD (1) · James Gulley, M.D. (1) · Kartik Seghal, MD (1) · Monica Mita, MD (1) · Nancy Lee, MD (1) · Panayiotis Savvides, MD (1) · Romana Netea-Maier (1) · Sasan Fazeli, MD (1) · Scot C. Remick, MD (1) · Siddharth Sheth, DO MPH (1) · Sonal Gupta, MD PhD (1)
PMID 27240885, PMID 17985341, PMID 19372041, PMID 19602035, PMID 19735988, PMID 20145168, PMID 21367608, PMID 32179633, PMID 32364844, PMID 35521657
2014 (2), P30CA043703 (2), 2023 (1), R01CA246553 (1), U01CA062502 (1), U01CA076576 (1)